Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Ajay Nirula"'
Autor:
Kara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert W. Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Manish C. Choudhary, Rinki Deo, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron, Judith S. Currier, ACTIV-2/A5401 Study Team, Michael D. Hughes, Davey M. Smith
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
In April 2021, Eli Lilly voluntarily asked the FDA to revoke the Emergency Use Authorization for the monoclonal antibody bamlanivimab due to reduced susceptibility in vitro to SARS-CoV-2 variants, not for safety. In this work, authors carry out a pla
Externí odkaz:
https://doaj.org/article/0b6a4f1c3538405a88228d712db0338b
Autor:
Kara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert W. Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Manish C. Choudhary, Rinki Deo, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron, Judith S. Currier, ACTIV-2/A5401 Study Team, Michael D. Hughes, Davey M. Smith
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/855e78e2e14745259e95ef61051904bc
Autor:
Gregory Huhn, Josh Poorbaugh, Lin Zhang, Stephanie Beasley, Ajay Nirula, Jennifer Brothers, Sharon Welbel, James Wilson, Sheena Gillani, Kathleen M. Weber, Ralph Morack, Kody Keckler, Robert J. Benschop
Publikováno v:
PLoS ONE, Vol 17, Iss 9 (2022)
Background The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-inf
Externí odkaz:
https://doaj.org/article/a5cae4cf70494a3f8c5b1cc1795dd4a5
Autor:
Lin Zhang, Josh Poorbaugh, Michael Dougan, Peter Chen, Robert L. Gottlieb, Gregory Huhn, Stephanie Beasley, Montanea Daniels, Thi Ngoc Vy Trinh, Melissa Crisp, Joshua Joaquin Freitas, Peter Vaillancourt, Dipak R. Patel, Ajay Nirula, Nicole L. Kallewaard, Richard E. Higgs, Robert J. Benschop
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundNeutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically efficacious when administered early, decreasing hospitalization and mortality in patients with mild or moderate COVID-19. We investigated the effects of receiving mAbs (
Externí odkaz:
https://doaj.org/article/2989bd8ebc794edc93eb3dcb73825ce6
Autor:
Justin Stebbing, Venkatesh Krishnan, Stephanie deBono, Silvia Ottaviani, Giacomo Casalini, Peter J Richardson, Vanessa Monteil, Volker M Lauschke, Ali Mirazimi, Sonia Youhanna, Yee‐Joo Tan, Fausto Baldanti, Antonella Sarasini, Jorge A Ross Terres, Brian J Nickoloff, Richard E Higgs, Guilherme Rocha, Nicole L Byers, Douglas E Schlichting, Ajay Nirula, Anabela Cardoso, Mario Corbellino, the Sacco Baricitinib Study Group
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 8, Pp n/a-n/a (2020)
Abstract Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID‐19 infection via prop
Externí odkaz:
https://doaj.org/article/1380cc483c5c41d9b6607430fabfaf22
Autor:
Jadwiga Bienkowska, Norm Allaire, Alice Thai, Jaya Goyal, Tatiana Plavina, Ajay Nirula, Megan Weaver, Charlotte Newman, Michelle Petri, Evan Beckman, Jeffrey L Browning
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e112545 (2014)
A subset of patients with autoimmune diseases including rheumatoid arthritis (RA) and lupus appear to be exposed continually to interferon (IFN) as evidenced by elevated expression of IFN induced genes in blood cells. In lupus, detection of endogenou
Externí odkaz:
https://doaj.org/article/5aee8698067a47a9b3e3c6ff98a387d3
Autor:
Jay Tuttle, Edit Drescher, Jesus Abraham Simón-Campos, Paul Emery, Maria Greenwald, Alan Kivitz, Hyungmin Rha, Pia Yachi, Christina Kiley, Ajay Nirula
Publikováno v:
New England Journal of Medicine. 388:1853-1862
Autor:
Matthew M. Riggs, Emmanuel Chigutsa, Ahmed Elmokadem, Jenny Y. Chien, Eric Burroughs Jordie, Ajay Nirula, Tim Knab
Publikováno v:
Clinical Pharmacology and Therapeutics
Neutralizing monoclonal antibodies (mAb), novel therapeutics for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), have been urgently researched from the start of the pandemic
Autor:
Jack Knorr, Russell Perry, Peter Chen, Corey Hebert, Richard E. Higgs, Mark D. Williams, Joseph Boscia, Bharat Mocherla, Masoud Azizad, Princy Kumar, Robert L. Gottlieb, Paul Klekotka, Dipak R. Patel, Ajay Nirula, Imad Shawa, Andra L. Blomkalns, Andrew C. Adams, Gregory D. Huhn, Kenneth L. Custer, Lei Shen, Timothy R. Holzer, Jason Morris, Philip J. Ebert, Andrew E. Schade, Jacob Van Naarden, Blaze investigators, Gerard J. Oakley, Jose Cardona, Janelle Sabo, Matan C. Dabora, Daniel Skovronsky, Chad Crystal, Barry Heller, Awawu Igbinadolor, Michael Dougan
Publikováno v:
Clinical Infectious Diseases. 75:e440-e449
Background Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods This Phase 3 portion of the BLAZE-1 tr
Autor:
Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller
Publikováno v:
The New England Journal of Medicine
Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive i